When Concentra bought iTeos earlier this year, the headline number—$10.047 per share—looked underwhelming. In fact, it was at a slight discount to what the stock was trading at the day before. But buried in the fine print was something intriguing: a non‑transferable contingent value right (CVR) promising iTeos shareholders maybe more later if the company … Continue reading Why Biotech Deals Keep Coming with CVRs
business
Biotech M&A – Three Trends to notice
Most biotech M&A coverage correctly highlights where capital is flowing, which therapeutic areas are hot, and which companies are poised to shape the future of medicine. For BD, corporate strategy, or investing, such information is useful. It gives context. It sets benchmarks. And it surfaces the big moves worth watching. But that's only part of … Continue reading Biotech M&A – Three Trends to notice
BK talks Biopharm 